While its biggest immunology drug Remicade showed moderate growth of 5.2%, the sales for Simponi and Stelara grew substantially.
FORBES: Johnson & Johnson's Earnings Buoyed By Pharma Strength
应用推荐
模块上移
模块下移
不移动